Skip to main content

Table 1 Patient and tumor characteristics (n = 204)

From: Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT

 

Nadir PSA < 0.06 ng/mL

(n = 157)

Nadir PSA ≥ 0.06 ng/mL

(n = 47)

 

P value

N

%

N

%

Age: ≤ 70 years

86

54.8

26

55.3

0.948

 > 70 years

71

45.2

21

44.7

GS: ≤ 7

68

43.3

16

34.0

0.257

8–10

89

56.7

31

66.0

Stage: T1-T2

93

60.4

21

46.7

0.102

T3–T4

61

39.6

24

53.3

PSA at presentation: ≤ 20 ng/mL

83

53.2

19

40.4

0.125

 > 20 ng/mL

73

46.8

28

59.6

Duration of ADT (months)

   

Mean

21.5

20.2

0.493

Median (IQR)

24.0 (9–36)

18.5 (8–36)

 

Duration of ADT

   

 ≤ 6 months

36 (23.4)

10 (21.7)

0.495

 ≤ 9 months

39 (25.3)

13 (28.3)

0.412

 ≤ 12 months

48 (31.2)

15 (32.6)

0.494

 ≤ 18 months

54 (35.1)

24 (52.2)

0.028

 ≤ 24 months

103 (66.9)

28 (60.9)

0.280

 > 24 months

51 (33.1)

18 (39.1)

0.280

Missing

3 (1.9%)

1 (2.1%)

 

Mean RT dose (Gy)

73.8 (Range 70–78)

73.1 (Range 70–78)

0.113

Time to nPSA (months

Median (IQR)

6.0 (3.2–10.0)

N/A*

 
  1. *Patients in the unfavorable group did not reach nPSA of 0.06 ng/mL